Showing results 1 to 5 of 5
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial Proceeding/Conference:Journal of Clinical Oncology | 2014 | 46 | ||
Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology | 2012 | 35 | ||
Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology | 2011 | 59 | ||
7-Mar-2014 | 60 | |||
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Journal:Molecular Cancer Therapeutics | 2018 | 16 |